Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption

Journal of Medical Virology

Volumn 79, Issue 8, 2007, Pages 1047-1054

  Rozera, G ^a   Abbate, I ^a   D'Offizi, G ^a   Corpolongo, A ^a   Narciso, P ^a   Vlassi, C ^a   Martini, F ^a   Calcaterra, S ^a   Capobianchi, M R ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Genetic heterogeneity; HIV 1; Provirus; Structured therapy interruption; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; PROVIRUS DEOXYRIBONUCLEIC ACID; RITONAVIR; STAVUDINE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL PROTOCOL; DRUG INDICATION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; MALE; MULTIPLE CYCLE TREATMENT; TREATMENT INDICATION; VIREMIA; VIROLOGY; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HIV-1; HUMANS; MIDDLE AGED; PHYLOGENY; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34347342653     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20895     Document Type: Article

References (27)

1. Abbate I, Cappiello G, Longo R, Ursitti A, Spano A, Calcaterra S, Dianzani F, Antinori A, Capobianchi MR. 2005. Cell membrane proteins and quasispecies compartmentalization of CSF and plasma HIV-1 from aids patients with neurological disorders. Infect Genet Evol 5:247-523.
2. Ananworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Sirivichayakul S, Cavassini M, Karrer U, Genne D, Nuesch R, Vernazza P, Bernasconi E, Leduc D, Satchell C, Yerly S, Perrin L, Hill A, Perneger T, Phanuphak P, Furrer H, Cooper D, Ruxrungtham K, Hirschel B, Staccato Study Group, Swiss HIV Cohort Study. 2006. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: Results of the Staccato randomised trial. Lancet 368:459-465.
3. Benson CA. 2006. Structured treatment interruptions - New finfings. Top HIV Med 14:107-111.
4. Bongiovanni M, Casana M, Tincati C, d'Arminio Monforte A. 2006. Treatment interruptions in HIV-infected subjects. J Antimicrob Chemother 58:502-505.
5. Desiré N, Dehee A, Schneider V, Jacomet C, Goujon C, Girard PM, Rozenbaum W, Nicolas JC. 2001. Quantification of human immunodeficiency virus type 1 proviral load by a TaqMan realtime PCR assay. J Clin Microbiol 39:1303-1310.
6. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fatkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C, Strategies for Management of Antiretroviral Therapy (SMART) Study Group. 2006. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 355:2283-2296.
7. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512-517.
8. Garbuglia AR, Calcaterra S, D'Offizi G, Topino S, Narciso P, Lillo F, Girardi E, Capobianchi MR. 2004. HIV-1 DNA burden dynamics in CD4 T cells and monocytes in patients undergoing a transient therapy interruption. J Med Virol 74:373-381.
9. Garcia F, Plana M, Ortiz GM, Bonhoeffer S, Soriano A, Vidal C, Cruceta A, Arnedo M, Gil C, Pantaleo G, Pumarola T, Gallart T, Nixon DF, Miro JM, Gatell JM. 2001. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 15:F29-F40.
10. Hoen B, Fournier I, Charreau I, Lacabaratz C, Burgard M, Arvieux C, Bouvet E, Pariente F, Aboulker JP, Venet A, Rouzioux C, Raffi F. 2004. Structured treatment interruptions in primary HIV infection: Final results of the multicenter prospective PRIMSTOP pilot trial. 11th Conference on Retroviruses and Opportunistic Infection (February 8-11, 2004), San Francisco, California, 2004.
11. Kaufmann DE, Lichterfeld M, Altfeld M, Addo MM, Johnston MN, Lee PK, Wagner BS, Kalife ET, Strick D, Rosenberg ES, Walker BD. 2004. Limited durability of viral control following treated acute HIV infection. PLoS Med 1:e36.
12. Kinloch S, Perrin L, Hoen B, Lampe F, Phillips A, Goh L, Tsoukas C, Sonnerborg A, Autran B, Andersson J, El Habib R, Theofan G, Carter N, Cooper D. 2004. Evaluation of 2 therapeutic HIV vaccination regimens in HAART-treated primary HIV infection subjects following analytical treatment interruption: QUEST PROB3005, a randomized, placebo-controlled study. 11th Conference on Retroviruses and Opportunistic Infection (February 8-11, 2004), San Francisco, California, 2004.
13. Lafeuillade A, Poggi C, Hittinger G., et al. 2003. Predictors of plasma human immunodeficiency virus type 1 RNA control after discontinuation of highly active antiretroviral therapy initiated at acute infection combined with structured treatment interruptions and immune-based therapies. J Infect Dis 188:1426-1432.
14. Lori F, Lewis MG, Xu J, Varga G, Zinn DE, Jr., Crabbs C, Wagner W, Greenhouse J, Silvera P, Yalley-Ogunro J, Tinelli C, Lisziewicz J. 2000. Control of SIV rebound through structured treatment interruptions during early infection. Science 290:1591-1593.
15. Mc Nearney T, Hornickova Z, Markham R, Birdwell A, Arens M, Saah A, Ratner L. 1992. Relationship of human immunodeficiency virus type 1 sequence heterogeneity to stage of disease. Proc Natl Acad Sci USA 89:10247-10251.
16. Mirò J, Plana M, Ortiz G, Maleno M, Arnedo M, del Rio A, Claramante X, Garcia A, Lazzari E, Joseph J, Pumarola T, Nixon DF, Gallart T, Gatell JM. 2002. Structured treatment interruptions (STI) in patients receiving HAART since primary HIV-1 infection (PHI): Spontaneous control of viremia in about one third of cases after the first cycles off therapy. 9th Conference on Retroviruses and Opportunistic Infection (February 24-28, 2002), Seattle, WA, 2002.
17. Oxenius A, Price DA, Gunthard HF, Dawson SJ, Fagard C, Perrin L, Fischer M, Weber R, Plana M, Garcia F, Hirschel B, McLean A, Phillips RE. 2002. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA 99:13747-13752.
18. Pai NP, Tulsky JP, Lawrence J, Colford JM, Jr., Reingold AL. 2005. Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Cochrane Database Syst Rev. 4:CD005482.
19. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338:853-860.
20. Piketty C, Weiss L, Bachir-Cherif S, Assoumou L, Burgard M, Ragnaud JM, Bentata M, Girard PM, Rouzioux C, Costagliola D, The ANRS 116 SALTO study group. 2006. Time to HAART resume after structured treatment interruption is strongly associated with HIV DNA level in PBMC at interruption: Results of the ANRS 116 SALTO trial. XVI International AIDS Conference, Toronto, Canada, 13-18 August 2006, WE AB0205.
21. Pilcher CD, Eron JJ, Jr., Galvin S, Gay C, Cohen MS. 2004. Acute HIV revisited: New opportunities for treatment and prevention. J Clin Invest 113:937-945.
22. Richman DD. 2001. HIV chemother. Nature 410:995-1001.
23. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, Robbins GK, D'Aquila RT, Goulder PJ, Walker BD. 2000. Immune control of HIV-1 after early treatment of acute infection. Nature 407:523-526.
24. Ruiz L, Martinez-Picado J, Romeu J, Paredes R, Zayat MK, Marfil S, Negredo E, Sirera G, Tural C, Clotet B. 2000. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS 14:397-403.
25. Touloumi G, Pantazis N, Antoniou A, Stirnadel HA, Walker SA, Porter K, CASCADE Collaboration. 2006. Highly active antiretroviral therapy interruption: Predictors and virological and immunologic consequences. J Acquir Immune Defic Syndr 42:554-561.
26. Troyer RM, Collins KR, Abraha A, Fraundorf E, Moore DM, Krizan RW, Toossi Z, Colebunders RL, Jensen MA, Mullins JI, Vanham G, Arts EJ. 2005. Changes in Human Immunodeficiency Virus type 1 fitness and genetic diversity during disease progression. J Virol 79:9006-9018.
27. Yerly S, Gunthard HF, Fagard C, Joos B, Perneger TV, Hirschel B, Perrin L, The Swiss HIV Cohort Study. 2004. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. AIDS 18:1951-1964.